Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.22% | 248.92% | 156.32% | 21.28% | 5.19% |
| Total Depreciation and Amortization | 2.53% | 3.40% | -5.25% | 19.02% | -15.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.19% | 10.30% | 26.22% | -18.89% | -20.15% |
| Change in Net Operating Assets | 70.90% | -189.95% | 4,610.53% | 16.89% | 77.32% |
| Cash from Operations | 23.68% | -135.29% | 714.09% | 24.39% | 27.24% |
| Capital Expenditure | -6.81% | -767.21% | 54.14% | 80.27% | -46.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 127.39% | -221.17% | -180.51% | 164.51% | -626.26% |
| Cash from Investing | 125.27% | -224.41% | -181.85% | 161.72% | -720.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,507.14% | -99.61% | 23,953.33% | -99.97% | 20,901.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 2,507.14% | -97.70% | 3,953.33% | -99.98% | 39,746.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.80% | -247.72% | 488.16% | 84.33% | 132.42% |